摘要
目的探讨美多巴联合司来吉兰治疗帕金森病患者临床效果及其安全性评价。方法本研究病例来源于2014年8月至2015年8期间我院收治的原发性帕金森病患者86例,依据随机数字表法分为观察组43例与对照组43例。观察组采用美多巴联合司来吉兰治疗,对照组仅采用美多巴治疗。两组疗程均为3个月。结果观察组总有效率(86.05%)高于对照组(67.44%)(P<0.05);两组Webster评分治疗后明显减少(P<0.05);观察组Webster评分治疗后低于对照组(P<0.05);两组MDRSPD评分治疗后明显减少(P<0.05);观察组MDRSPD评分治疗后低于对照组(P<0.05);两组均未见严重用药不良反应。结论美多巴联合司来吉兰治疗帕金森病患者临床效果显著,且安全可靠。
Objective To investigate the effect of Madopar and selegiline treatment in patients with Parkinson＇s disease clinical effect and its safety evaluation. Methods 86 cases of primary Parkinson＇s disease in our hospital during the period from August 2014 to August 2015,according to the random number table method were randomly divided into observation group 43 cases and control group 43 cases. Observation group were treated with Madopar and selegiline,control group only with madopar,the treatment last for 3 months. Results The total effective rate of the observation group（86.05%）was higher than that of the control group（67.44%）（P0.05）;Webster score of the two groups were significantly reduced after treatment（P0.05）;Webster score of observation group were lower than control group after treatment（P0.05）;MDRSPD score of the two groups were significantly decreased after treatment（P0.05）;MDRSPD score of observation group were lower than the control group after treatment（P0.05）;two groups had no serious with adverse drug reactions. No serious adverse drug reactions were found in the two groups. ConclusionMadopar and our to Gilan treatment in patients with Parkinson＇s disease clinical effect is remarkable,and is safe and reliable.
出处
《国际精神病学杂志》
2016年第4期645-647,共3页
Journal Of International Psychiatry
